|
🐜
|
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
76 auth.
Yuankai Shi,
K. Lei,
Yuming Jia,
Bingqiang Ni,
Zhiyong He,
M. Bi,
Xicheng Wang,
Jianhua Shi,
Ming Zhou,
Qiang Sun,
Guolei Wang,
Dongji Chen,
Y. Shu,
Lianke Liu,
Zhongliang Guo,
...
Yong Liu,
Junquan Yang,
Ke Wang,
Ke Xiao,
Lin Wu,
T. Yi,
Debin Sun,
Ma-fei Kang,
Tianjiang Ma,
Y. Mao,
Jinsheng Shi,
T. Tang,
Yan Wang,
P. Xing,
D. Lv,
W. Liao,
Zhiguo Luo,
Bin Wang,
Xiaohong Wu,
Xiao-Li Zhu,
Shuhua Han,
Q. Guo,
Rongyu Liu,
Zhiwei Lu,
Jianyong Zhang,
J. Fang,
Changlu Hu,
Yinghua Ji,
Guolong Liu,
Hong Lu,
Dedong Wu,
Junhong Zhang,
Shuyang Zhu,
Zheng Liu,
W. Qiu,
F. Ye,
Yan Yu,
Yanqiu Zhao,
Q. Zheng,
Jun Chen,
Z. Pan,
Yiping Zhang,
Wen-fei Lian,
B. Jiang,
B. Qiu,
Guojun Zhang,
Hua Zhang,
Yanju Chen,
Yuan Chen,
H. Duan,
Manxiang Li,
Shengming Liu,
Lijun Ma,
H. Pan,
Xia Yuan,
Xu Yuan,
Yulong Zheng,
E. Gao,
Li Zhao,
Shumin Wang,
Can Wu
|
4 |
2021 |
4
🐜
|
